相关临床试验
6
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2006
进行中（未招募）
3
50.0%
已完成
3
50.0%
暂无批准数据
- Basilea Pharmaceutica has initiated FORWARD-IM, a phase 3 registrational study evaluating fosmanogepix for treating invasive mold infections in adults, with completion expected in Q1 2028. - Fosmanogepix is a first-in-class broad-spectrum antifungal with novel mechanism of action, showing activity against multidrug-resistant molds including Aspergillus, Fusarium, and Mucorales fungi. - The study will enroll approximately 220 patients across two cohorts, with the first cohort randomizing 160 patients 2:1 to fosmanogepix versus standard-of-care therapy. - This marks the second phase 3 study for fosmanogepix, following the FAST-IC trial initiated in September 2024 for candidemia and invasive candidiasis treatment.
- Pfizer has acquired Amplyx Pharmaceuticals, gaining rights to fosmanogepix, a novel Phase 2 antifungal compound that could address drug-resistant fungal infections with mortality rates of 30-80%. - The acquisition strengthens Pfizer's anti-infectives portfolio with fosmanogepix being the potential first new antifungal drug class in 20 years, offering both IV and oral formulations. - The deal builds on Pfizer's initial equity investment from December 2019 and includes Amplyx's early-stage pipeline of antiviral and antifungal therapies.
